Search clinical trials for: Radioligand [¹¹C]CHDI-00485626

Total 6 results

CHDI Foundation, Inc.
Universitaire Ziekenhuizen KU Leuven

Terminated

iMagemHTT: FIH Evaluation of Novel Mutant Huntingtin PET Radioligands [¹¹C]CHDI-00485180-R and [¹¹C]CHDI-00485626

Huntington Disease

Belgium
Universitaire Ziekenhuizen KU Leuven
CHDI Foundation, Inc.

Completed

Dosimetry of [11C]CHDI-180R and [11C]CHDI-626.

Huntington Disease

Belgium
Nanhua University
Buddhist Tzu Chi General Hospital; Solano Semiconductor Technology., LTD.

Completed

Effect of Health Promotion on Allergic Rhinitis by Infrared-C Ray Irradiation

Allergic Rhinitis
University of Chicago
National Cancer Institute (NCI)

Completed

Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission

Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) | Adult Acute Myeloid Leukemia... and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma

Recurrent Adult Hodgkin Lymphoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma

United States

Search clinical trials for: Radioligand [¹¹C]CHDI-00485626

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Rwanda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations